In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.
Jay S. Duker, MD
Advertisement
Articles by Jay S. Duker, MD
Study aims to identify methodology for least amount of variation, greatest test-retest reliability
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Modern Retina
1
Clinical Trials at the Summit 2026: First-time data, AI, and the next generation of retinal treatments
2
The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS
3
Geographic atrophy: When lesion borders cannot be graded
4
FDA guidance to help accelerate cell and gene therapies
5